 | Up a level |
Nappi, Rossella E; Johnson, Kimball A; Stute, Petra; Blogg, Martin; English, Marci; Morga, Antonia; Scrine, Ludmila; Siddiqui, Emad; Ottery, Faith D (2024). Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2). (In Press). Menopause The North American menopause Society 10.1097/GME.0000000000002354
Johnson, Kimball A; Martin, Nancy; Nappi, Rossella E; Neal-Perry, Genevieve; Shapiro, Marla; Stute, Petra; Thurston, Rebecca C; Wolfman, Wendy; English, Marci; Franklin, Catherine; Lee, Misun; Santoro, Nanette (2023). Efficacy and Safety of Fezolinetant in Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. The Journal of clinical endocrinology and metabolism, 108(8), pp. 1981-1997. The Endocrine Society 10.1210/clinem/dgad058
Lederman, Samuel; Ottery, Faith D; Cano, Antonio; Santoro, Nanette; Shapiro, Marla; Stute, Petra; Thurston, Rebecca C; English, Marci; Franklin, Catherine; Lee, Misun; Neal-Perry, Genevieve (2023). Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. The lancet, 401(10382), pp. 1091-1102. Elsevier 10.1016/S0140-6736(23)00085-5
